ImmuPharma PLC Profitability Analysis
| IMM Stock | 1.12 0.01 0.88% |
Net Loss | First Reported 2012-09-30 | Previous Quarter -193.9 K | Current Value -193.9 K | Quarterly Volatility 958.4 K |
For ImmuPharma PLC profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ImmuPharma PLC to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ImmuPharma PLC utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ImmuPharma PLC's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ImmuPharma PLC over time as well as its relative position and ranking within its peers.
ImmuPharma |
ImmuPharma PLC Return On Asset vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ImmuPharma PLC's current stock value. Our valuation model uses many indicators to compare ImmuPharma PLC value to that of its competitors to determine the firm's financial worth. ImmuPharma PLC is rated fifth overall in return on equity category among its peers. It is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ImmuPharma PLC's earnings, one of the primary drivers of an investment's value.ImmuPharma Return On Asset vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
ImmuPharma PLC |
| = | -1.11 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
ImmuPharma PLC |
| = | -0.43 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
ImmuPharma PLC Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ImmuPharma PLC, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ImmuPharma PLC will eventually generate negative long term returns. The profitability progress is the general direction of ImmuPharma PLC's change in net profit over the period of time. It can combine multiple indicators of ImmuPharma PLC, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 6 M | 6.3 M | |
| Operating Income | -3.1 M | -3.2 M | |
| Income Before Tax | -3.4 M | -3.6 M | |
| Total Other Income Expense Net | -355.9 K | -338.1 K | |
| Net Loss | -2.9 M | -3.1 M | |
| Income Tax Expense | -497.1 K | -522 K | |
| Net Loss | -7.4 M | -7 M | |
| Net Loss | -2.9 M | -3.1 M | |
| Net Interest Income | 1 K | 1.1 K | |
| Interest Income | 3 K | 2.9 K | |
| Change To Netincome | 3 M | 3.1 M |
ImmuPharma Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ImmuPharma PLC. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ImmuPharma PLC position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ImmuPharma PLC's important profitability drivers and their relationship over time.
Use ImmuPharma PLC in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ImmuPharma PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ImmuPharma PLC will appreciate offsetting losses from the drop in the long position's value.ImmuPharma PLC Pair Trading
ImmuPharma PLC Pair Trading Analysis
The ability to find closely correlated positions to ImmuPharma PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ImmuPharma PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ImmuPharma PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ImmuPharma PLC to buy it.
The correlation of ImmuPharma PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ImmuPharma PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ImmuPharma PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ImmuPharma PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your ImmuPharma PLC position
In addition to having ImmuPharma PLC in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Business Supplies Thematic Idea Now
Business Supplies
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Business Supplies theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Business Supplies Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in ImmuPharma Stock
To fully project ImmuPharma PLC's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ImmuPharma PLC at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ImmuPharma PLC's income statement, its balance sheet, and the statement of cash flows.